SCHEMBL9900897

SCHEMBL9900897

[c]1ccnc(N(c2ccccc2)N2CCOCC2)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.36
LMNA P02545 3/20 0.36
TSHR P16473 1/20 0.36
METAP1 P53582 2/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 5/20 0.33
KDM4E B2RXH2 3/20 0.33
GLA P06280 2/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 1/20 0.33
PTK2 Q05397 1/20 0.32
FGFR1 P11362 1/20 0.32
KDR P35968 1/20 0.32
EPHB4 P54760 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18335244 0.84 METAP1 (0.43) PKMLMNATSHRMETAP1ALOX15
SCHEMBL12614645 0.71 NPC1 (0.39) PKMLMNATSHRALDH1A1KDM4E
SCHEMBL6100741 0.69 FGFR1 (0.40) PKMLMNATSHRMETAP1ALOX15
SCHEMBL27965427 0.68 HTT (0.43) LMNATSHRMAPK1ALDH1A1KDM4E
SCHEMBL27760171 0.67 KMT2A (0.44) LMNAMETAP1ALOX15MAPK1ALDH1A1
SCHEMBL27921621 0.67 CAMK2D (0.46) METAP1ALOX15MAPK1ALDH1A1HSD17B10
SCHEMBL27739748 0.67 JAK2 (0.50) LMNAKDM4E
SCHEMBL3131793 0.67 CHEK1 (0.35) PKMLMNATSHRMETAP1ALOX15
SCHEMBL28865660 0.67 CDK2 (0.40) PKMLMNATSHRMAPK1ALDH1A1
SCHEMBL11120096 0.67 LMNA (0.41) PKMLMNATSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PKM 56/4885LMNA 2103/4885TSHR 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.